Commercial Strategy                 Stents                 Orthopedics                 Wounds                 Bionic Technologies Australia		PolyNovo will develop a broad array of NovoSorbTM polymer products to meet the specific needs of differing disease indications and surgical practices. Initially the company has chosen to develop products that will meet the needs of the following strategic market segments. These represent a balanced portfolio of opportunity in unmet clinical needs, time to market, regulatory process and commercialisation outcomes. NovoSorb’sTM value will be increased by multiple partnering in different device areas. The product value will be amplified by the efforts expended in these partnerships or through grants and collaborative efforts. This process has been optimised by selection of the highest caliber groups and companies to collaborate with. Specifically this can be thought of as two streams of activity. Licensing transactions and break-out opportunities. The licensing deals are generally in applications where to skills and costs required to be successful are beyond PolyNovo’s current abilities. The break-out opportunities are where PolyNovo can partner with Australian groups to build value in a device concept prior to partnering with a large medical device manufacturer. PolyNovo owns all of the NovoSorbTM intellectual property. We are active in growing the patent portfolio, expanding the device potential and value of NovoSorbTM and related polymers. Our patent estate is currently being examined, waiting for examination or in application form depending on how recently it was filed.